UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No.   )*

 

Soleno Therapeutics, Inc.

(Name of Issuer)

 

Common Stock, $0.001 par value per share

(Title of Class of Securities)

 

834203200

(CUSIP Number)

 

May 8, 2023

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)

 

Rule 13d-1(c)

 

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

1.  

NAMES OF REPORTING PERSONS

 

Vivo Opportunity Fund Holdings, L.P.

2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)   ☐         (b)  

3.  

SEC USE ONLY

 

4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.  

SOLE VOTING POWER

 

8,418,093 (1)(2)

  6.  

SHARED VOTING POWER

 

0

  7.  

SOLE DISPOSITIVE POWER

 

8,418,093 (1)(2)

  8.  

SHARED DISPOSITIVE POWER

 

0

9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

8,418,093 (1)(2)

10.  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES    

 

11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

19.99% (2)

12.  

TYPE OF REPORTING PERSON

 

PN

 

(1)Represents 8,418,093 shares underlying warrants (the “Warrants”) to purchase Common Stock, par value $0.001 per share (the “Common Stock”), of the Issuer that are exercisable within 60 days of this Statement. The Warrants are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
(2)The Warrants contain initial provisions preventing the Warrants from being exercised if such exercise would result in the holder obtaining greater than 19.99% of the Issuer’s voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon exercise of the Warrants in full, and do not give effect to the blocking provisions. Such blocking provisions will terminate upon approval by the Issuer’s stockholders of the issuance of shares underlying the Warrants.

 

2

 

 

1.  

NAMES OF REPORTING PERSONS

 

Vivo Opportunity, LLC

2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)           (b)  

3.  

SEC USE ONLY

 

4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.  

SOLE VOTING POWER

 

8,418,093 (1)(2)

  6.  

SHARED VOTING POWER

 

0

  7.  

SOLE DISPOSITIVE POWER

 

8,418,093 (1)(2)

  8.  

SHARED DISPOSITIVE POWER

 

0

9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

8,418,093 (1)(2)

10.  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES    

 

11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

19.99% (2)

12.  

TYPE OF REPORTING PERSON

 

OO

 

3

 

 

Item 1. Issuer
     
  (a) Name of Issuer:
     
    Soleno Therapeutics, Inc. (the “Issuer”)
     
  (b) Address of Issuer’s Principal Executive Offices:
     
    203 Redwood Shores Pkwy, Suite 500 Redwood City, CA 94065
     
Item 2. Filing Person
     
  (a) – (c) Name of Persons Filing; Address; Citizenship:
     
    (i) Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership; and
     
    (ii) Vivo Opportunity, LLC, a Delaware limited liability company. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The address of the principal business office of the Reporting Persons is 192 Lytton Avenue, Palo Alto, CA 94301.
     
  (d) Title of Class of Securities:
     
    Common Stock, par value $0.001 per share (“Common Stock”).
     
  (e) CUSIP Number:   834203200

 

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
       
  (a) Broker or dealer registered under Section 15 of the Act;
       
  (b) Bank as defined in Section 3(a)(6) of the Act;
       
  (c) Insurance company as defined in Section 3(a)(19) of the Act;
       
  (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
       
  (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

 

4

 

 

  (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
       
  (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
       
  (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
  (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
       
  (j) A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
       
  (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
     
    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

 

Item 4. Ownership.
   
  (a) and (b) Amount beneficially owned:
     
  The information set forth in rows 5 through 11 of the cover pages is incorporated by reference into this Item 4.
     
    The shares reported in this Schedule 13G represent 8,418,093 shares underlying warrants (the “Warrants”) to purchase Common Stock of the Issuer that are exercisable within 60 days of this Statement. The Warrants are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., and may be deemed to beneficially own the shares of Common Stock underlying securities held directly by Vivo Opportunity Fund Holdings, L.P. The voting members of Vivo Opportunity, LLC are Gaurav Aggarwal, Hongbo Lu, Kevin Dai, Frank Kung, and Michael Chang, none of whom has individual voting or investment power with respect to these securities and each of whom disclaims beneficial ownership of such securities.
     
    The Warrants contain initial provisions preventing the Warrants from being exercised if such exercise would result in the holder obtaining greater than 19.99% of the Issuer’s voting securities. However, the amounts reported in this Item 4 represent the number of shares of Common Stock that would be issuable upon exercise of the Warrants in full, and do not give effect to the blocking provisions. Such blocking provisions will terminate upon approval by the Issuer’s stockholders of the issuance of shares underlying the Warrants.

 

5

 

 

  (c) Number of shares as to which such person has:

 

Reporting Person  Sole Voting Power   Shared Voting Power   Sole Dispositive Power   Shared Dispositive Power   Percentage of Common Stock Outstanding 
                     
Vivo Opportunity Fund Holdings, L.P.   8,418,093           0    8,418,093           0    19.99%*
Vivo Opportunity, LLC   8,418,093    0    8,418,093    0    19.99%*

 

*The percent of class was calculated based upon 8,168,788 shares of Common Stock outstanding as of May 4, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2023, plus the shares of Common Stock underlying Warrants held by Vivo Opportunity Fund Holdings, L.P., after giving effect to the blocking provisions described above, which prevent the Reporting Persons from exercising Warrants in excess of 19.99% of the Issuer’s voting securities prior to the receipt of stockholder approval.

 

Item 5. Ownership of Five Percent or Less of a Class.
   
  Not applicable.
   
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
   
  Not applicable.
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
   
  Not applicable.
   
Item 8. Identification and Classification of Members of the Group.
   
  Not applicable.
   
Item 9. Notice of Dissolution of Group.
   
  Not applicable.
   
Item 10. Certification.
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

6

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: May 15, 2023

 

VIVO OPPORTUNITY FUND HOLDINGS, L.P,  
   

By:

Vivo Opportunity, LLC

 
Its: General Partner  
   
/s/ Gaurav Aggarwal  

Name: 

Gaurav Aggarwal

 
Title: Managing Member  
   
VIVO OPPORTUNITY, LLC  
   
/s/ Gaurav Aggarwal  

Name:

Gaurav Aggarwal

 
Title: Managing Member  

 

7

 

 

EXHIBIT INDEX

 

Exhibit   
99.1  Joint Filing Statement

 

8

 

EXHIBIT 99.1

 

Joint Filing Agreement

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

 

Date: May 15, 2023

 

VIVO OPPORTUNITY FUND HOLDINGS, L.P,  
   

By:

Vivo Opportunity, LLC

 
Its: General Partner  
   
/s/ Gaurav Aggarwal  

Name: 

Gaurav Aggarwal

 
Title: Managing Member  
   
VIVO OPPORTUNITY, LLC  
   
/s/ Gaurav Aggarwal  

Name:

Gaurav Aggarwal

 
Title: Managing Member